Suppr超能文献

高密度脂蛋白携带的肺表面活性物质蛋白B可预测1型糖尿病患者发生心血管疾病的风险。

Pulmonary surfactant protein B carried by HDL predicts incident CVD in patients with type 1 diabetes.

作者信息

Shao Baohai, Snell-Bergeon Janet K, Pyle Laura L, Thomas Katie E, de Boer Ian H, Kothari Vishal, Segrest Jere, Davidson William S, Bornfeldt Karin E, Heinecke Jay W

机构信息

Department of Medicine, University of Washington, Seattle, WA, USA.

Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO, USA.

出版信息

J Lipid Res. 2022 Apr;63(4):100196. doi: 10.1016/j.jlr.2022.100196. Epub 2022 Mar 14.

Abstract

Atherosclerotic CVD is the major cause of death in patients with type 1 diabetes mellitus (T1DM). Alterations in the HDL proteome have been shown to associate with prevalent CVD in T1DM. We therefore sought to determine which proteins carried by HDL might predict incident CVD in patients with T1DM. Using targeted MS/MS, we quantified 50 proteins in HDL from 181 T1DM subjects enrolled in the prospective Coronary Artery Calcification in Type 1 Diabetes study. We used Cox proportional regression analysis and a case-cohort design to test associations of HDL proteins with incident CVD (myocardial infarction, coronary artery bypass grafting, angioplasty, or death from coronary heart disease). We found that only one HDL protein-SFTPB (pulmonary surfactant protein B)-predicted incident CVD in all the models tested. In a fully adjusted model that controlled for lipids and other risk factors, the hazard ratio was 2.17 per SD increase of SFTPB (95% confidence interval, 1.12-4.21, P = 0.022). In addition, plasma fractionation demonstrated that SFTPB is nearly entirely bound to HDL. Although previous studies have shown that high plasma levels of SFTPB associate with prevalent atherosclerosis only in smokers, we found that SFTPB predicted incident CVD in T1DM independently of smoking status and a wide range of confounding factors, including HDL-C, LDL-C, and triglyceride levels. Because SFTPB is almost entirely bound to plasma HDL, our observations support the proposal that SFTPB carried by HDL is a marker-and perhaps mediator-of CVD risk in patients with T1DM.

摘要

动脉粥样硬化性心血管疾病(CVD)是1型糖尿病(T1DM)患者的主要死因。高密度脂蛋白(HDL)蛋白质组的改变已被证明与T1DM患者中普遍存在的CVD相关。因此,我们试图确定HDL携带的哪些蛋白质可能预测T1DM患者发生CVD的风险。我们采用靶向串联质谱法(MS/MS),对参加1型糖尿病前瞻性冠状动脉钙化研究的181名T1DM受试者的HDL中的50种蛋白质进行了定量分析。我们使用Cox比例回归分析和病例队列设计来测试HDL蛋白质与新发CVD(心肌梗死、冠状动脉搭桥术、血管成形术或冠心病死亡)之间的关联。我们发现,在所有测试模型中,只有一种HDL蛋白质——肺表面活性物质蛋白B(SFTPB)——能够预测新发CVD。在一个控制了血脂和其他风险因素的完全调整模型中,SFTPB每增加一个标准差,风险比为2.17(95%置信区间,1.12 - 4.21,P = 0.022)。此外,血浆分级分离显示SFTPB几乎完全与HDL结合。尽管先前的研究表明,仅在吸烟者中,血浆中高水平的SFTPB与普遍存在的动脉粥样硬化相关,但我们发现,SFTPB能够独立于吸烟状态以及包括HDL-C、LDL-C和甘油三酯水平在内的一系列混杂因素,预测T1DM患者发生CVD的风险。由于SFTPB几乎完全与血浆HDL结合,我们的观察结果支持这样一种观点,即HDL携带的SFTPB是T1DM患者CVD风险的一个标志物——也许还是一个介导因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1691/9010748/ded1fa4a7216/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验